Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210855 | 0.98 | ALDH1A1 (0.39) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| Bromide SCHEMBL8665049 | 0.94 | ALDH1A1 (0.37) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL2913990 | 0.78 | ALDH1A1 (0.53) | ALDH1A1KDM4EGAAHSD17B10KMT2A | |
| SCHEMBL7045581 | 0.72 | BCL2 (0.50) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL16469702 | 0.71 | ALDH1A1 (0.43) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL16470407 | 0.69 | CYP1A2 (0.39) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| Benzene SCHEMBL27725171 | 0.69 | ALDH1A1 (0.68) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL5574323 | 0.68 | CYP2A6 (0.54) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL304403 | 0.68 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL4853659 | 0.66 | ALDH1A1 (0.72) | ALDH1A1KDM4EGAAHSD17B10HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1471887-B1 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ELAN PHARMA INT LTD (IE) | 2010-04-21 | — | — | EP | claimed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12569441-B2 | Microparticles and nanoparticles having negative surface charges | CYTODIGM, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240415774-A1 | DELAMANID-CONTAINING COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12070508-B2 | Microparticles and nanoparticles having sulfate groups on the surface | CYTODIGM, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240139141-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4351520-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117750946-A | Novel particulate compositions comprising sialic acid binding ligands | 希托迪格姆公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240041770-A1 | MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGES | CYTODIGM INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20220175959-A1 | MICROPARTICLES AND NANOPARTICLES HAVING SULFATE GROUPS ON THE SURFACE | CYTODIGM, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220168423-A1 | NANOPARTICLES OF INDIRUBIN, DERIVATIVES THEREOF AND METHODS OF MAKING AND USING SAME | CYTODIGM, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022108934-A1 | NOVEL DRUG DELIVERY COMPOSITION AND PROCESS FOR BLOOD-BRAIN BARRIER CROSSING | PHOSPHOREX, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220142935-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | CYTODIGM, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022076435-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | PHOSPHOREX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3975997-A1 | MICROPARTICLES AND NANOPARTICLES HAVING SULFATE GROUPS ON THE SURFACE | Phosphorex, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114072130-A | Microparticles and nanoparticles having sulfate groups on the surface | 法斯瑞斯公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20110033529-A1 | ORAL PHARMACEUTICAL PARICALCITOL FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-02-10 | — | — | US | disclosed |
| US-20100098770-A1 | SIROLIMUS PHARMACEUTICAL FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-04-22 | — | — | US | disclosed |
| US-20090202649-A1 | FENOFIBRATE FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569441-B2 | Microparticles and nanoparticles having negative surface charges | PTEN, ADH1A, ACP1 | ACHE 3087/4885ALDH1A1 222/4885KDM4E 2512/4885 |
| US-20240041770-A1 | MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGES | FLOT1, CD47, CLTA | ACHE 2907/4885ALDH1A1 2905/4885KDM4E 2383/4885 |
| US-20220168423-A1 | NANOPARTICLES OF INDIRUBIN, DERIVATIVES THEREOF AND METHODS OF MAKING AND USING SAME | PARK7, NQO1, NDUFS7 | ACHE 94/4885ALDH1A1 768/4885KDM4E 4351/4885 |
| US-20240139141-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | TUBAL3, TUBB6, TUBA1A | ACHE 308/4885ALDH1A1 316/4885KDM4E 2720/4885 |
| US-20100098770-A1 | SIROLIMUS PHARMACEUTICAL FORMULATIONS | RICTOR, MTOR, RPTOR | ACHE 4883/4885ALDH1A1 4707/4885KDM4E 674/4885 |
| US-20220142935-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | SIGLEC7, SIGLEC9, SELPLG | ACHE 3447/4885ALDH1A1 1668/4885KDM4E 4676/4885 |
| US-20110033529-A1 | ORAL PHARMACEUTICAL PARICALCITOL FORMULATIONS | PTH1R, CYP24A1, GCG | ACHE 4112/4885ALDH1A1 3058/4885KDM4E 2886/4885 |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | SIGLEC9, SIGLEC7, SELPLG | ACHE 4677/4885ALDH1A1 1402/4885KDM4E 4807/4885 |
| US-20090202649-A1 | FENOFIBRATE FORMULATIONS | HMGCR, PPARA, PPARD | ACHE 4659/4885ALDH1A1 1420/4885KDM4E 1213/4885 |
| US-20240415774-A1 | DELAMANID-CONTAINING COMPOSITION | NOP2, DDOST, PML | ACHE 479/4885ALDH1A1 1189/4885KDM4E 3842/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | ACHE 4188/4885ALDH1A1 2989/4885KDM4E 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.